Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats

Cesare Maltoni, Franco Minardi, Carmine Pinto, Fiorella Belpoggi, Luciano Bua

Research output: Contribution to journalArticle

Abstract

Tamoxifen was submitted to carcinogenicity bioassays on Sprague-Dawley rats (of the colony used at the Cancer Research Center in the Castle of Bentivoglio of the European Ramazzini Foundation of Oncology and Environmental Sciences) at the dose of 3.3 mg/kg b.w., by stomach tube, in three experiments. In the first experiment the drug was administered once daily, 6 days a week to male and female rats, 8 weeks old at start for their life span. In the second experiment, the drug was administered to female rats, 12 weeks old at start, once daily for 8 consecutive days every 8 weeks for their life span. In the third experiment the drug was administered to female rats, 56 weeks old at start, 6 times weekly for 40 weeks; and then the animals were kept alive for their life span. In the first experiment, a mild increase in hepatocarcinomas with low grading was detected. In the first and second experiments, a borderline increase in uterine malignancies was found. No carcinogenic effect was observed in the third experiment. In the three experiments, tamoxifen showed a strong, long-lasting chemopreventive effect on mammary benign tumors and cancers. The presented data also indicate that tamoxifen treatment reduces the incidence of other tumors: pituitary adenomas, adrenal pheochromocytomas, islet cell pancreatic tumors, Leydig cell testicular tumors, and polyps of the uterus.

Original languageEnglish
Pages (from-to)469-512
Number of pages44
JournalAnnals of the New York Academy of Sciences
Volume837
Publication statusPublished - Dec 26 1997

Fingerprint

Tamoxifen
Rats
Pharmaceutical Preparations
Leydig Cell Tumor
Breast Neoplasms
Tumors
Neoplasms
Experiments
Testicular Neoplasms
Pituitary Neoplasms
Pheochromocytoma
Polyps
Ecology
Biological Assay
Uterus
Sprague Dawley Rats
Stomach
Incidence
Research
Oncology

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats. / Maltoni, Cesare; Minardi, Franco; Pinto, Carmine; Belpoggi, Fiorella; Bua, Luciano.

In: Annals of the New York Academy of Sciences, Vol. 837, 26.12.1997, p. 469-512.

Research output: Contribution to journalArticle

@article{090954619d2a47a99e3015ce57a98860,
title = "Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats",
abstract = "Tamoxifen was submitted to carcinogenicity bioassays on Sprague-Dawley rats (of the colony used at the Cancer Research Center in the Castle of Bentivoglio of the European Ramazzini Foundation of Oncology and Environmental Sciences) at the dose of 3.3 mg/kg b.w., by stomach tube, in three experiments. In the first experiment the drug was administered once daily, 6 days a week to male and female rats, 8 weeks old at start for their life span. In the second experiment, the drug was administered to female rats, 12 weeks old at start, once daily for 8 consecutive days every 8 weeks for their life span. In the third experiment the drug was administered to female rats, 56 weeks old at start, 6 times weekly for 40 weeks; and then the animals were kept alive for their life span. In the first experiment, a mild increase in hepatocarcinomas with low grading was detected. In the first and second experiments, a borderline increase in uterine malignancies was found. No carcinogenic effect was observed in the third experiment. In the three experiments, tamoxifen showed a strong, long-lasting chemopreventive effect on mammary benign tumors and cancers. The presented data also indicate that tamoxifen treatment reduces the incidence of other tumors: pituitary adenomas, adrenal pheochromocytomas, islet cell pancreatic tumors, Leydig cell testicular tumors, and polyps of the uterus.",
author = "Cesare Maltoni and Franco Minardi and Carmine Pinto and Fiorella Belpoggi and Luciano Bua",
year = "1997",
month = "12",
day = "26",
language = "English",
volume = "837",
pages = "469--512",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Results of three life-span experimental carcinogenicity and anticarcinogenicity studies on tamoxifen in rats

AU - Maltoni, Cesare

AU - Minardi, Franco

AU - Pinto, Carmine

AU - Belpoggi, Fiorella

AU - Bua, Luciano

PY - 1997/12/26

Y1 - 1997/12/26

N2 - Tamoxifen was submitted to carcinogenicity bioassays on Sprague-Dawley rats (of the colony used at the Cancer Research Center in the Castle of Bentivoglio of the European Ramazzini Foundation of Oncology and Environmental Sciences) at the dose of 3.3 mg/kg b.w., by stomach tube, in three experiments. In the first experiment the drug was administered once daily, 6 days a week to male and female rats, 8 weeks old at start for their life span. In the second experiment, the drug was administered to female rats, 12 weeks old at start, once daily for 8 consecutive days every 8 weeks for their life span. In the third experiment the drug was administered to female rats, 56 weeks old at start, 6 times weekly for 40 weeks; and then the animals were kept alive for their life span. In the first experiment, a mild increase in hepatocarcinomas with low grading was detected. In the first and second experiments, a borderline increase in uterine malignancies was found. No carcinogenic effect was observed in the third experiment. In the three experiments, tamoxifen showed a strong, long-lasting chemopreventive effect on mammary benign tumors and cancers. The presented data also indicate that tamoxifen treatment reduces the incidence of other tumors: pituitary adenomas, adrenal pheochromocytomas, islet cell pancreatic tumors, Leydig cell testicular tumors, and polyps of the uterus.

AB - Tamoxifen was submitted to carcinogenicity bioassays on Sprague-Dawley rats (of the colony used at the Cancer Research Center in the Castle of Bentivoglio of the European Ramazzini Foundation of Oncology and Environmental Sciences) at the dose of 3.3 mg/kg b.w., by stomach tube, in three experiments. In the first experiment the drug was administered once daily, 6 days a week to male and female rats, 8 weeks old at start for their life span. In the second experiment, the drug was administered to female rats, 12 weeks old at start, once daily for 8 consecutive days every 8 weeks for their life span. In the third experiment the drug was administered to female rats, 56 weeks old at start, 6 times weekly for 40 weeks; and then the animals were kept alive for their life span. In the first experiment, a mild increase in hepatocarcinomas with low grading was detected. In the first and second experiments, a borderline increase in uterine malignancies was found. No carcinogenic effect was observed in the third experiment. In the three experiments, tamoxifen showed a strong, long-lasting chemopreventive effect on mammary benign tumors and cancers. The presented data also indicate that tamoxifen treatment reduces the incidence of other tumors: pituitary adenomas, adrenal pheochromocytomas, islet cell pancreatic tumors, Leydig cell testicular tumors, and polyps of the uterus.

UR - http://www.scopus.com/inward/record.url?scp=0031587504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031587504&partnerID=8YFLogxK

M3 - Article

C2 - 9472359

AN - SCOPUS:0031587504

VL - 837

SP - 469

EP - 512

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -